admin
- COVAX announces 600,000 doses of the AstraZeneca/Oxford vaccine licensed to Serum Institute of India have arrived in Accra, Ghana; further deliveries to Abidjan, Cote d’Ivoire are expected this week
- Final first round of allocations for doses of AstraZeneca/Oxford and Pfizer-BioNTech vaccines, to the majority of countries and economies participating in the COVAX Facility, anticipated to be published in coming days
- Beginning of global rollout means that, as readiness criteria are met and doses produced, vaccines will be shipped to Facility participants on a rolling basis
India
healthysoch
GENEVA/NEW YORK/OSLO/ New Delhi, February 24, 2021:
Today, Ghana became the first country outside India to receive COVID-19 vaccine doses shipped via the COVAX Facility. This is a historic step towards our goal to ensure equitable distribution of COVID-19 vaccines globally, in what will be the largest vaccine procurement and supply operation in history. The delivery is part of a first wave of arrivals that will continue in the coming days and weeks.
On 23 February, COVAX shipped 600,000 doses of the AstraZeneca/ Oxford vaccine, from the Serum Institute of India (SII) from Pune, India to Accra, Ghana, arriving on the morning of 24 February. The arrival in Accra is the first batch shipped and delivered in Africa by the COVAX Facility as part of an unprecedented effort to deliver at least 2 billion doses of COVID-19 vaccines by the end of 2021.
COVAX is co-led by Gavi, the Vaccine Alliance, the World Health Organization (WHO) and the Coalition for Epidemic Preparedness Innovations (CEPI), working in partnership with UNICEF as well as the World Bank, civil society organisations, manufacturers, and others.
“COVAX’s mission is to help end the acute phase of the pandemic as quickly as possible by enabling global equitable access to COVID-19 vaccines. Today’s delivery takes us another step closer to this goal and is something the whole world can be proud of. Over the coming weeks, COVAX must deliver vaccines to all participating economies to ensure that those most at risk are protected, wherever they live. We need governments and businesses now to recommit their support for COVAX and help us defeat this virus as quickly as possible,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance.
“We will not end the pandemic anywhere unless we end it everywhere,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Today is a major first step towards realizing our shared vision of vaccine equity, but it’s just the beginning. We still have a lot of work to do with governments and manufacturers to ensure that vaccination of health workers and older people is underway in all countries within the first 100 days of this year.”
Dr Richard Hatchett, CEO of CEPI said: “This is a landmark moment in our efforts to get life-saving vaccine to the world. The fact that we now have multiple safe and effective vaccines against COVID-19 developed in record time is testament to the scientific community and industry rising to the challenge of this pandemic. With this shipment we also see the global community, through COVAX, responding to the challenge of delivering these vaccines to those who need them most. Let us celebrate this as a moment of global solidarity in the struggle against the pandemic. But there is still much to do. With the increased spread of COVID-19 variants, we have entered a new and less predictable phase of the pandemic. It is crucial that the vaccines we have developed are shared globally, as a matter of the greatest urgency, to reduce the prevalence of disease, slow down viral mutation, and bring the pandemic to an end.”
“Today marks the historic moment for which we have been planning and working so hard. With the first shipment of doses, we can make good on the promise of the COVAX Facility to ensure people from less wealthy countries are not left behind in the race for life-saving vaccines,” said Henrietta Fore, UNICEF Executive Director. “In the days ahead, frontline workers will begin to receive vaccines, and the next phase in the fight against this disease can begin – the ramping up of the largest immunization campaign in history. Each step on this journey brings us further along the path to recovery for the billions of children and families affected around the world.”
The vaccines arrived on a flight from Mumbai, via Dubai, where the flight also collected a shipment of syringes from a Gavi-funded stockpile at UNICEF’s regional Supply Hub.
Over the past several months, COVAX partners have been supporting governments and partners, particularly for AMC-eligible participants, in readiness efforts, in preparation for this moment. This includes assisting with the development of national vaccination plans, support for cold chain infrastructure, as well as stockpiling of half a billion syringes and safety boxes for their disposal, masks, gloves and other equipment to ensure that there is enough equipment for health workers to start vaccinating priority groups as soon as possible.
In order for doses to be delivered to Facility participants via this first allocation round, several critical pieces must be in place, including confirmation of national regulatory authorisation criteria related to the vaccines delivered, indemnification agreements, national vaccination plans from AMC participants, as well as other logistical factors such as export and import licenses.
As participants fulfil the above criteria and finalise readiness preparations, COVAX will issue purchase orders to the manufacturer and ship and deliver doses via an iterative process. This means deliveries for this first round of allocation will take place on a rolling basis and in tranches.
Building on the interim distribution forecast published earlier this month, final information on the first round allocations, covering the majority of Facility participants, is expected to be communicated in the coming days.
COVAX has built a diverse portfolio of vaccines suitable for a range of settings and populations, and is on track to meet its goal of delivering at least 2 billion doses of vaccine to participating countries around the globe in 2021, including at least 1.3 billion donor-funded doses to the 92 lower-income Facility participants supported by the Gavi COVAX AMC.
healthysoch
